No Data
No Data
Director Makes Bold Move With Major Stock Purchase in Zenas BioPharma!
Insider Purchase: Director at $ZBIO Buys 10,000 Shares
Zenas BioPharma Reports Strong 2024 Momentum, Eyes 2025 Milestones In Obexelimab Trials for Lupus, Multiple Sclerosis, And IgG4-RD
Zenas BioPharma Announces Objectives for 2025
Express News | Zenas Biopharma- Cash Equivalents, Short-Term Investments as of Dec 31 to Fund Operating Expenses & Capex Requirements Into Q4 2026
Express News | Zenas Biopharma : Topline Results From Phase 2 Trial in Relapsing Multiple Sclerosis (Moonstone) Expected in Q3 2025
Unlock the Full List